CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of Directors.
Ms. Collins is a recognized leader in cell and gene therapy, molecular diagnostics, life sciences, and therapeutics. Prior to her most recent position as CEO of Human Longevity, Inc., she served as the CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics. Prior to GE, Ms. Collins served as President and CEO of GenVec, a publicly-traded vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses. Earlier in her career, she served as President and CEO of Sequoia Pharmaceuticals, Inc., and as President of Clinical Micro Sensors, Inc., a wholly-owned subsidiary of Motorola. She also spent 17 years with Baxter Healthcare in a variety of executive roles, including as President of Oncology and as Vice President and General Manager of Cell Therapies. Ms. Collins began her career with Abbott Laboratories.
“Cindy has a track record of building innovative life science businesses and leading highly-productive teams. She has delivered tremendous results for the companies she has led, and I am pleased to welcome her to our Board of Directors,” said James C. Mullen, Chairman of Board of Directors, Editas Medicine.
“I am pleased to join Editas Medicine’s Board of Directors. Editas Medicine is a leader in genome editing, and I look forward to working with the team during this unprecedented moment in medicine as they bring revolutionary genome editing medicines to people living with serious diseases,” said Ms. Collins.
Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana, and her MBA from The University of Chicago Booth School of Business. She is also a member of the board of directors for the ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics, DermTech, Cavidi, and Biocare Medical.
In addition, the Company announced that Boris Nikolic, M.D., stepped down from the Board. Dr. Nikolic, Managing Director of bng0 and Biomatics Capital, joined the board in August 2015.
“We are appreciative of the many contributions Boris has made to Editas Medicine. We wish him well in his continued business endeavors,” said Mr. Mullen.
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Source: Editas Medicine, Inc.